FAST-Trac Award
The FAST-Trac Award from FAST funds translational research to develop treatments, tools, and clinical readiness for Angelman Syndrome, emphasizing innovation and impact on patient outcomes.
Funder: Foundation for Angelman Syndrome Therapeutics (FAST)
Due Dates: Rolling (no fixed deadline)
Funding Amounts: Up to $150,000/year for 1–2 years (larger budgets considered with justification); 5% indirect costs allowed; $3,000 travel stipend included.
Summary: Supports translational research to accelerate the development of treatments, tools, and clinical readiness for Angelman Syndrome.
Key Information: Letter of Intent (LOI) required before full application; nonprofit institutions and PhD/MD-level investigators eligible.
Description
The FAST-Trac Award, offered by the Foundation for Angelman Syndrome Therapeutics (FAST), is designed to catalyze translational research focused on developing and advancing new treatments for Angelman Syndrome (AS). The program targets projects in gene modification, disease modification, symptom-alleviating therapeutics, high-throughput drug screening platforms, and the creation of innovative disease models. It also supports the development of biomarkers, outcome measures, and clinical trial readiness, including the collection of natural history data and preparation of clinical sites. The award aims to generate impactful data that can support further research funding and publication, with an emphasis on translational applications that benefit the AS community.
